HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
April 10, 2021 08:31 ET
|
Hookipa Pharma Inc
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202Early data on HB-201 monotherapy show an...
HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook
March 18, 2021 07:00 ET
|
Hookipa Pharma Inc
Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidatesFollow-on offering strengthened cash...
HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021
March 09, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, March 09, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine
March 04, 2021 07:00 ET
|
Hookipa Pharma Inc
Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells2-vector approach resulted in tumor cures and...
HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life Sciences Conference
March 03, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, March 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare Conference
February 16, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters’ Option
December 11, 2020 16:20 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Dec. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Preferred Stock
December 08, 2020 22:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferred Stock
December 08, 2020 16:01 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability
December 07, 2020 06:00 ET
|
Hookipa Pharma Inc
Results support first proof of concept for HOOKIPA’s replicating investigational single-vector immunotherapy in oncologyData demonstrate responses and stable disease in some head and neck cancer...